公开(公告)号：US20230314452A1

公开(公告)日：2023-10-05

申请号：US18021085

申请日：2021-08-12

Applicant: Roche Diagnostics Operations, Inc.

Inventor： Peter Kastner ,  Vinzent Rolny ,  Ursula-Henrike Wienhues-Thelen ,  Andre Ziegler ,  David Conen ,  Stefan Osswald ,  Michael Kuehne

IPC: G01N33/68

CPC classification number: G01N33/6896 ,  G16H50/30

Abstract: The present invention relates to a method for assessing whether a subject has experienced one or more silent infarcts in a subject, said method comprising a) determining the amount of IGFBP7 in a sample from the subject, b) comparing the amount determined in step a) to a reference, and c) assessing whether a subject has experienced one or more silent infarcts. The present invention further relates to a method for predicting silent infarcts and/or cognitive decline, and methods for assessing and monitoring of the extent of silent small and large noncortical and cortical infarcts in a subject. Further encompassed by the present invention are the corresponding uses.

公开(公告)号：US20210199659A1

公开(公告)日：2021-07-01

申请号：US17186163

申请日：2021-02-26

Applicant: Roche Diagnostics Operations, Inc.

Inventor： Vinzent Rolny ,  Sandra Rutz ,  David Morgenstern ,  Boris Pinchuk ,  Christina Zimmermann ,  Martin Klammer ,  Franziska Sonner

IPC: G01N33/573 ,  G01N33/574

Abstract: The present disclosure relates to the finding that thymidine kinase 1 (TK-1) represents a valuable biomarker in a method for determining a Prognostic Index (PI) for risk stratification of a patient with aggressive B-cell lymphoma, especially diffuse large B-cell lymphoma (DLBCL), to the use of TK-1 in such PI and to a PI comprising the marker TK-1.

公开(公告)号：US20210181211A1

公开(公告)日：2021-06-17

申请号：US17176797

申请日：2021-02-16

Applicant: Roche Diagnostics Operations, Inc. ,  Universiteit Maastricht ,  Academisch Zickenhuis Maastricht

Inventor： Peter Kastner ,  Andre Ziegler ,  Ursula-Henrike Wienhues-Thelen ,  Vinzent Rolny ,  Manuel Dietrich ,  Ulrich Schotten

IPC: G01N33/68

Abstract: The present invention relates to a method for assessing atrial fibrillation in a subject, said method comprising the steps of determining the amount of TFPI-2 in a sample from the subject, and comparing the amount of TFPI-2 to a reference amount, whereby atrial fibrillation is to be assessed. Moreover, the present invention relates to methods for assessing anticoagulation therapy and to methods for predicting the risk of stroke of a subject. Said methods are based on the determination of the amount of TFPI-2 in a sample from the subject.

公开(公告)号：US20200300869A1

公开(公告)日：2020-09-24

申请号：US16899629

申请日：2020-06-12

Applicant: Roche Diagnostics Operations, Inc.

Inventor： Ursula-Henrike Wienhues-Thelen ,  Johann Karl ,  Peter Kastner ,  Vinzent Rolny ,  Andre Ziegler ,  David Conen

IPC: G01N33/68

Abstract: The present disclosure demonstrates a method for predicting the risk of stroke of a subject and a method for improving the prediction accuracy of a clinical stroke risk score. The methods are based on the determination of the amount of Angiopoietin-2 (Ang-2) and/or the amount of Insulin-like growth factor-binding protein 7 (IGFBP7) in a sample from a subject. Moreover, disclose is the use of i) the biomarker Ang-2 and/or the biomarker IGFBP7, and/or ii) at least one detection agent that specifically binds to Ang-2 and/or at least one detection agent that specifically binds to IGFBP7 in a sample from a subject for predicting the risk of stroke of said subject.

公开(公告)号：US20190162737A1

公开(公告)日：2019-05-30

申请号：US16264779

申请日：2019-02-01

Applicant: Roche Diagnostics Operations, Inc. ,  Maastricht University Medical Center

Inventor： Johann Karl ,  Peter Kastner ,  Roberto Latini ,  Serge Masson ,  Ursula-Henrike Wienhues-Thelen ,  Andre Ziegler ,  Manuel Dietrich ,  Ulrich Schotten ,  Vinzent Rolny

IPC: G01N33/68

Abstract: The present invention relates to a method for assessing atrial fibrillation in a subject, said method comprising the steps of determining the amount of ESM-1 in a sample from the subject, and comparing the amount of ESM-1 to a reference amount, whereby atrial fibrillation is to be assessed. Moreover, the present invention relates to a method for diagnosing heart failure and/or at least one structural or functional abnormality of the heart associated with heart failure.